Αρχική World News FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma World News FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Από Ogkologos - 6 Νοεμβρίου, 2025 460 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Opinion: The Government should not be choosing between investing in staff... 27 Ιουλίου, 2022 How I Learned to Advocate for Myself During Cancer: “Your Stories”... 18 Οκτωβρίου, 2022 Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults 25 Φεβρουαρίου, 2019 Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent... 5 Μαρτίου, 2026 Φόρτωση περισσοτέρων HOT NEWS A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... Incidence, Relative Risk and Risk Factors for Chronic Comorbidities in Long-Term... Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling...